Brief: Renovorx Engages Oklahoma University (Ou) Health As First Clinical Site
21/12/2023 14:49
Dec 21 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX ENGAGES OKLAHOMA UNIVERSITY (OU) HEALTH AS FIRST
CLINICAL SITE IN PREPARATION FOR THE PIVOTAL PHASE III COUGAR
CLINICAL TRIAL IN BILE DUCT CANCER
Source text for Eikon: ID:nBwc4MKH1a
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer